openPR Logo
Press release

HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca

03-21-2019 12:53 PM CET | Media & Telecommunications

Press release from: SMi Group

HPAPI 2019 Conference: Exclusive Interview Released with

Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing.

Peter said:

“The HPAPI market is becoming more entrenched across the Pharma industry. Historically major pharma and some specialist contract manufacturers have led the field in design and application, but the more general toxic nature of new products has required many more companies to consider investment in contained facilities. Further to this, new drug modalities such as ADCs (antibody-drug conjugates) have presented enhanced containment challenges due to the elevated toxicity of some of the components. Finally, the toxicity of some modern inhaler and other device products has raised the importance of containment in device-related process approaches including dry powder and aseptic filling processes.”

“For me personally, the problem is often being involved in the early stages of a project to ensure that exposure control is properly considered, and optimal strategies and technologies are applied. In my opinion there are too many simplistic design or equipment selection tools which are used blindly without an understanding of their relevance and validity. In some cases these can lead to excessively conservative technology decisions which present significant operability and maintenance issues for the final user.”

The full interview is available in the Download Centre on the website.

Key sessions to be discussed in the area of containment include – Antibody-drug conjugate manufacturing, adaptation of containment designs to cope with the high demands of HPAPIs and the challenges verifying containment performance of a HPAPI OSD facility.

Joining Peter on Day Two of the conference will be Dr Thomas Nittoli, Director, Regeneron; Dr Jeff Parry, Senior Formulation Scientist, AstraZeneca and Mr Nigel Saunders, Technical Engineer – SME Containment, GSK.

Sponsors include: BSP Pharmaceuticals | Minakem | PCi Pharma Services | SafeBridge Consultants Inc. | Solo Containment

SMi offer unique sponsorship, exhibition and branding packages, tailored to complement your company’s marketing strategy. Contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi-online.co.uk

Conference Organisers

India House, 45 Curlew Street, London, SE1 2ND

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca here

News-ID: 1665853 • Views: 485

More Releases from SMi Group

NATO Focused Presentations to Feature at Mobile Deployable Communications 2020
SMi Reports: A series of NATO focused presentations will be featured at the Mobile Deployable Communications Conference in Warsaw, Poland in January 2020. Next spring, the US Army will be deploying 20,000 soldiers to Europe, where they will be taking part in the huge Defender-Europe 20 exercise alongside 17,000 allied troops. Defender 20 is just the latest in a series of multinational exercises in Europe over the past year, demonstrating the importance
SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020 – Speakers Announce …
SMi Reports: the agenda and speaker overview of the upcoming SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020, in London is now available to view. SMi Group is delighted to announce the return of the successful Superbugs & Superdrugs Conference for its 22nd year, taking place on 30th and 31st March 2020 at the Holiday Inn Kensington Forum in London. Antibiotics have long been one of the most important pharmaceuticals
Stuart Whitehead (SES), Joint Chief of Staff J6, to share his perspectives on ne …
SMi Reports: Stuart Whitehead from the Exercise Bold Quest this year, will be presenting at the Network Centric Warfare Conference in February 2020. Exercise Bold Quest 19.1 (BQ19.1), the latest in a series of Coalition Capability Demonstration and Assessment events, seeks to improve communication and information sharing across a wide variety of coalition networks and resources. Fifteen countries and NATO Headquarters participated in the exercise in Finland earlier this year, alongside
Insight into the Latest Developments in Oligonucleotide Delivery Systems
SMi Group are proud to present the new RNA Therapeutics Focus Day - Oligonucleotide Delivery Systems. The Focus Day will be held on the 18th of February 2020 and will present sessions that showcase a myriad of delivery approaches such as: optimising nanoparticle delivery to treat cancer and fibrosis; a review of common NA-LNP tolerability concerns to improve safety of nucleic acid therapeutics and the utility of light-triggered liposomes for

All 5 Releases


More Releases for HPAPI

Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Researc …
This report studies the global High Performance Active Pharmaceutical Ingredients (HPAPI) market status and forecast, categorizes the global High Performance Active Pharmaceutical Ingredients (HPAPI) market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bristol-Myers Squibb Novartis Sanofi Aventis Pfizer Lonza Novasep Hospira
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report
SMi’s HPAPI 2018 Conference: Exclusive Interview Released with HPAPI Project S …
SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin: Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety
Exclusive Interview Released with HPAPI Project Services
SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin: Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety
Introducing the 2nd Annual HPAPI Conference this May 2018
SMi is delighted to announce its 2nd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 21st - 22nd May 2018. Registration is now open! Conference Overview: The global market for Highly Potent Active Pharmaceutical Ingredients is currently largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have